U.S. markets closed

Jafron Biomedical Co.,Ltd. (300529.SZ)

Shenzhen - Shenzhen Delayed Price. Currency in CNY
Add to watchlist
54.69-1.36 (-2.43%)
At close: 3:04PM CST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close56.05
Bid54.69 x 0
Ask54.70 x 0
Day's Range54.49 - 56.49
52 Week Range47.30 - 103.00
Avg. Volume11,877,216
Market Cap44.053B
Beta (5Y Monthly)-0.28
PE Ratio (TTM)42.13
EPS (TTM)1.30
Earnings DateOct 19, 2021 - Oct 25, 2021
Forward Dividend & Yield0.66 (1.18%)
Ex-Dividend DateMay 12, 2021
1y Target Est79.08
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for 300529.SZ

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Jafron Biomedical Announces Global Advisory Board

      ZHUHAI, China, June 21, 2021 (GLOBE NEWSWIRE) -- Jafron Biomedical, a pioneer in the blood purification industry, announced it's founding the Global Advisory Board, which includes the world’s top medical experts in clinical research and critical care medicine. The six members of the recently founded Global Advisory Board include: Prof. Claudio Ronco, Full Professor of Nephrology at the University of Padova, Italy; Prof. Rinaldo Bellomo, Head of Research of the Department of Intensive Care at the